ALMAC Launches RAPIDD: A complete set of solutions aimed at
accelerating entry into early stage clinical development
Almac Science aura un stand à la
CRO-Biotech B4B-Connection
Almac understand the critical timelines in drug development
and the key advantages our clients gain in significantly reducing
development timelines through achieving milestones earlier,
minimising cash-burn, quicker return on investment and gaining
competitive advantage.
Rapidd™ offers a complete set of solutions aimed at accelerating
entry into early stage clinical development. Rapidd™ is a lean,
efficient, integrated solution from selection of pre-clinical
candidate to Phase I regulatory submission.
Almac, in collaboration with a selection of preferred CROs,
provides world class talent delivering a unique drug development
package leading to completion of Phase I regulatory submission in
under 12 months.